<DOC>
	<DOCNO>NCT01711970</DOCNO>
	<brief_summary>This prospective , open label , dose escalating , Phase I/II study , measure mainly safety tolerability combination intravenous administration VB-111 paclitaxel patient platinum resistant ovarian cancer .</brief_summary>
	<brief_title>A Phase I/II Trial VB-111 Paclitaxel Recurrent Platinum-Resistant Müllerian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients age &gt; 18 Histologically confirm epithelial ovarian , peritoneal , fallopian tube cancer , uterine papillary serous carcinoma ( UPSC ) , gynecologic malignant mixed müllerian tumor ( MMMTs ) . Must prior platinum platinum base therapy . Eastern Cooperative Oncology Group ( ECOG ) status 01 . Platinum resistant refractory disease within 6 month complete receive platinum taxane contain regimen Measurable disease Adequate bone marrow hematological function . Must recover acute toxicity prior treatment Prior treatment antiangiogenic agent exclusion criterion . No prior GI perforation , GI obstruction involvement bowel image Known hypersensitivity Cremophor EL . However , participant eligible prior paclitaxel reaction , subsequently tolerate drug rechallenge . No patient receive investigational therapy past 30 day dose . More 3 prior line chemotherapy recurrent cancer . History active malignancy , superficial basal cell superficial squamous cell , carcinoma situ cervix within last 2 year . Life expectancy le 3 month CTC Grade 1 great neuropathy ( motor sensory ) comorbidity prior taxane exposure , diabetes . Inadequately controlled hypertension prior history hypertensive crisis hypertensive encephalopathy . New York Heart Association ( NYHA ) Grade II great congestive heart failure . History myocardial infarction unstable angina within 6 month prior study Day 1 . History stroke transient ischemic attack within 6 month prior Day 1 . Known CNS disease , except treat brain metastasis Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 . History hemoptysis ( 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>